PURPOSE: Metastatic renal cell carcinoma (mRCC) sometimes presents with an indolent course without any significant symptoms. Here, the potential impact of active surveillance (AS) on clinical outcomes in asymptomatic or minimally symptomatic mRCC patients was retrospectively evaluated. METHODS: mRCC patients who were followed up with deferred treatment for the purpose of AS between 2000 and 2012 were enrolled. Patient and disease characteristics, outcomes of AS and subsequent therapies, and predictive factors for rapid disease progression were analyzed. The primary endpoint was time-to-progression (TTP). RESULTS: First-line systemic therapy was deliberately deferred in 58 patients. During AS, the best overall responses were stable disease for 48 patients (83 %) and progressive disease (PD) for 10 patients (17 %), and 47 patients ultimately experienced disease progression at the time of data cutoff. With a median follow-up of 31.4 months, the median TTP was 12.4 months (95 % confidence interval 8.4-16.5) and median overall survival was not reached. After univariate and multivariate analyses for TTP, Karnofsky performance status <100 %, liver metastasis, and a time from diagnosis to AS of less than 1 year were found to be predictive factors for a shorter TTP. After PD, 30 patients received systemic treatment (14 sunitinib, 11 pazopanib, 4 immunotherapy, and 1 temsirolimus). The objective response rates were 71 % for sunitinib and 46 % for pazopanib, which were deemed comparable with historical controls. CONCLUSIONS: Asymptomatic or minimally symptomatic mRCC patients can be observed for a prolonged period of time without active treatment.
PURPOSE:Metastatic renal cell carcinoma (mRCC) sometimes presents with an indolent course without any significant symptoms. Here, the potential impact of active surveillance (AS) on clinical outcomes in asymptomatic or minimally symptomatic mRCC patients was retrospectively evaluated. METHODS: mRCC patients who were followed up with deferred treatment for the purpose of AS between 2000 and 2012 were enrolled. Patient and disease characteristics, outcomes of AS and subsequent therapies, and predictive factors for rapid disease progression were analyzed. The primary endpoint was time-to-progression (TTP). RESULTS: First-line systemic therapy was deliberately deferred in 58 patients. During AS, the best overall responses were stable disease for 48 patients (83 %) and progressive disease (PD) for 10 patients (17 %), and 47 patients ultimately experienced disease progression at the time of data cutoff. With a median follow-up of 31.4 months, the median TTP was 12.4 months (95 % confidence interval 8.4-16.5) and median overall survival was not reached. After univariate and multivariate analyses for TTP, Karnofsky performance status <100 %, liver metastasis, and a time from diagnosis to AS of less than 1 year were found to be predictive factors for a shorter TTP. After PD, 30 patients received systemic treatment (14 sunitinib, 11 pazopanib, 4 immunotherapy, and 1 temsirolimus). The objective response rates were 71 % for sunitinib and 46 % for pazopanib, which were deemed comparable with historical controls. CONCLUSIONS: Asymptomatic or minimally symptomatic mRCC patients can be observed for a prolonged period of time without active treatment.
Authors: Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245
Authors: K M Ardeshna; P Smith; A Norton; B W Hancock; P J Hoskin; K A MacLennan; R E Marcus; A Jelliffe; G Vaughan; D C Linch Journal: Lancet Date: 2003-08-16 Impact factor: 79.321
Authors: Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Staehler; Sylvie Negrier; Christine Chevreau; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Sibyl Anderson; Gloria Hofilena; Minghua Shan; Carol Pena; Chetan Lathia; Ronald M Bukowski Journal: J Clin Oncol Date: 2009-05-18 Impact factor: 44.544
Authors: Alvin S Wong; Kian-Tai Chong; Chin-Tiong Heng; David T Consigliere; Kesavan Esuvaranathan; Khai-Lee Toh; Benjamin Chuah; Robert Lim; James Tan Journal: Urol Oncol Date: 2008-04-24 Impact factor: 3.498
Authors: Gary Hudes; Michael Carducci; Piotr Tomczak; Janice Dutcher; Robert Figlin; Anil Kapoor; Elzbieta Staroslawska; Jeffrey Sosman; David McDermott; István Bodrogi; Zoran Kovacevic; Vladimir Lesovoy; Ingo G H Schmidt-Wolf; Olga Barbarash; Erhan Gokmen; Timothy O'Toole; Stephanie Lustgarten; Laurence Moore; Robert J Motzer Journal: N Engl J Med Date: 2007-05-31 Impact factor: 91.245
Authors: Robert J Motzer; Bernard Escudier; Stéphane Oudard; Thomas E Hutson; Camillo Porta; Sergio Bracarda; Viktor Grünwald; John A Thompson; Robert A Figlin; Norbert Hollaender; Gladys Urbanowitz; William J Berg; Andrea Kay; David Lebwohl; Alain Ravaud Journal: Lancet Date: 2008-07-22 Impact factor: 79.321
Authors: Cora N Sternberg; Ian D Davis; Jozef Mardiak; Cezary Szczylik; Eunsik Lee; John Wagstaff; Carlos H Barrios; Pamela Salman; Oleg A Gladkov; Alexander Kavina; Juan J Zarbá; Mei Chen; Lauren McCann; Lini Pandite; Debasish F Roychowdhury; Robert E Hawkins Journal: J Clin Oncol Date: 2010-01-25 Impact factor: 44.544
Authors: Brian I Rini; Tanya B Dorff; Paul Elson; Cristina Suarez Rodriguez; Dale Shepard; Laura Wood; Jordi Humbert; Linda Pyle; Yu-Ning Wong; James H Finke; Patricia A Rayman; James M G Larkin; Jorge A Garcia; Elizabeth R Plimack Journal: Lancet Oncol Date: 2016-08-03 Impact factor: 54.433
Authors: Michael R Harrison; Brian A Costello; Nrupen A Bhavsar; Ulka Vaishampayan; Sumanta K Pal; Yousef Zakharia; Heather S L Jim; Mayer N Fishman; Ana M Molina; Christos E Kyriakopoulos; Che-Kai Tsao; Leonard J Appleman; Benjamin A Gartrell; Arif Hussain; Walter M Stadler; Neeraj Agarwal; Russell K Pachynski; Thomas E Hutson; Hans J Hammers; Christopher W Ryan; Brant A Inman; Jack Mardekian; Azah Borham; Daniel J George Journal: Cancer Date: 2021-03-25 Impact factor: 6.860